E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Herpes Zoster and related complications |
|
E.1.1.1 | Medical condition in easily understood language |
Herpes Zoster (shingles) disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019974 |
E.1.2 | Term | Herpes zoster |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10019972 |
E.1.2 | Term | Herpes viral infections |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The study will be randomised into two groups based on the vaccination schedule in relation to the start of a chemotherapy cycle:
- The OnChemo group receives their first HZ/su vaccination at the start of a chemotherapy cycle
- The PreChemo group receives their first HZ/su vaccination at least 10 days before the start of a chemotherapy cycle
•To evaluate anti-gE humoral immune responses at Month 2 (M2), following a two-dose administration of the HZ/su vaccine (post-dose 2), as compared to placebo, in subjects with solid tumours receiving chemotherapy (PreChemo groups only)
•To evaluate the safety and reactogenicity following administration of the HZ/su vaccine as compared to placebo up to 30 days post last vaccination in subjects with solid tumours receiving chemotherapy |
|
E.2.2 | Secondary objectives of the trial |
PreChemo groups only:
•To evaluate vaccine response rate (VRR) in anti-gE humoral immunogenicity responses at post-dose 2 of HZ/su vaccine (M2)
•To evaluate gE-specific CD4+ T-cell immunogenicity responses at post-dose 2 of HZ/su vaccine (M2), versus placebo (in CMI sub-cohort)
•To evaluate VRR in gE-specific CD4+ T-cell mediated immunogenicity at post-dose 2 of HZ/su vaccine (M2) (in CMI sub-cohort)
•To characterize gE-specific CD4+ T-cell mediated immunogenicity responses at M0, M1 and M13 (in CMI sub-cohort)
PreChemo and OnChemo groups:
•To evaluate the anti-gE humoral response at post-dose 2 of HZ/su vaccine (M2), versus placebo (all subjects)
•To evaluate VRR in anti-gE humoral immunogenicity responses at post-dose 2 of HZ/su vaccine (all subjects HZ/su)
•To evaluate safety following administration of HZ/su vaccine, versus placebo, from 30 days post last vaccination until study end
•To characterize anti-gE humoral immunogenicity responses at M0, M1, M2, M6 and M13 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol
•Written informed consent obtained from the subject
•A male or female aged 18 years or older (and has reached the age of legal consent) at the time of study entry (i.e., when informed consent is signed)
•Subject who has been diagnosed with one or more solid tumours (defined as a solid malignancy, i.e., not a blood element malignancy)
•Subject who is receiving or will receive a cytotoxic or immunosuppressive chemotherapy (such that the study vaccine can be administered at the latest at the start of the second cycle of chemotherapy)
•Life expectancy of greater than one year
•Female subjects of non-childbearing potential may be enrolled in the study;
-Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause;
•Female subjects of childbearing potential may be enrolled in the study, if the subject:
-has practiced adequate contraception for 30 days prior to vaccination, and
-has a negative pregnancy test on the day of vaccination, and
-has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. |
|
E.4 | Principal exclusion criteria |
•Subjects receiving only newer, more targeted therapies if not taken together with a classical chemotherapy
•Chronic administration and/or planned administration of systemic glucocorticoids within one month prior to the first vaccine dose and up to Visit 3 (Month 2). Inhaled, intra-articularly injected, and topical steroids are allowed
•Previous vaccination against HZ or varicella within 12 months preceding the first dose of study vaccine/ placebo
•Planned administration during the study of a HZ vaccine (including an investigational or non-registered vaccine) other than the study vaccine
•Previous chemotherapy course less than one month before first study vaccination
•Occurrence of a varicella or HZ episode by clinical history within the 12 months preceding the first dose of study vaccine/ placebo
•History of allergic disease or reactions likely to be exacerbated by any component of the vaccine or study material and equipment
•Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
•HIV infection by clinical history;
•Acute disease and/or fever at the time of vaccination. Acute disease is defined as the presence of a moderate or severe illness with or without fever, but excludes the underlying malignancy, as well as the expected symptoms/signs associated with that disease or its treatment;
-Fever is defined as temperature ≥ 37.5°C /99.5°F on oral, axillary or tympanic setting, or ≥ 38.0°C /100.4°F on rectal setting. The preferred route for recording temperature in this study will be oral.
-Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever, may receive the first dose of study vaccine/ placebo at the discretion of the investigator.
•Any condition which, in the judgment of the investigator would make intramuscular injection unsafe;
•Pregnant or lactating female;
•Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 3 (i.e., 2 months after the last dose of study vaccine/ placebo). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
A. Anti-gE humoral immunogenicity with respect to components of the study/investigational vaccine.in terms of antibody (Ab) concentrations.
-Anti-gE Ab concentrations as determined by ELISA.
B. Occurrence of solicited local and general symptoms.
-Occurrence, intensity and duration of each solicited local symptom.
-Occurrence, intensity, duration and relationship to vaccination of each solicited general symptom.
C. Occurrence of Unsolicited adverse events (AEs).
-Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
D. Occurrence of Serious Adverse Events (SAEs).
-Occurrence and relationship to vaccination of SAEs.
E. Occurrence of AEs of specific interest.
-Occurrence and relationship to vaccination of any potential Immune Mediated Diseases (pIMDs). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
-At Month 2 (for A.)
Within 7 days (Days 0-6) after each vaccination (for B.)
-During 30 days (Days 0-29) after each vaccination (for C.)
-Up to 30 days post last vaccination (for D. and E.) |
|
E.5.2 | Secondary end point(s) |
A. For immunogenicity with respect to components of the study/investigational vaccine
-Anti-gE Ab concentrations as determined by ELISA at Month 0, Month 1, Month2, Month 6 (Visit 4, at the start of the last cycle of chemotherapy between months 4 and 13) and Month 13
-Vaccine response for anti-gE Abs at Month 1, Month 2, Month 6 (Visit 4, at the start of the last cycle of chemotherapy between months 4 and 13) and Month 13
-Frequencies of gE-specific CD4+ T-cells, expressing at least 2 activation markers (from among IFN-γ, IL-2, TNF-α and CD40 L), as determined by in vitro intracellular cytokine staining (ICS), at Month 0, Month 1, Month 2, and Month 13
-Vaccine response for gE-specific CD4+ T-cells expressing at least 2 activation markers (from among IFN-γ, IL-2, TNF-α and CD40L), as determined by in vitro ICS, at Month 1, Month 2 and Month 13
B. Occurrence of Serious Adverse Events (SAEs)
-Occurrence and relationship to vaccination of SAEs during the period starting after 30 days post last vaccination until study end
C. Occurrence of AEs of specific interest
-Occurrence of any pIMDs during the period starting after 30 days post last vaccination until study end |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
-At Month 0, Month 1, Month 6 (Visit 4, at the start of the last cycle of chemotherapy between months 4 and 13) and Month 13 (for A)
-During the period starting after 30 days post last vaccination until study end (Month 13) (for B and C) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity, Prevention |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Czech Republic |
France |
Korea, Republic of |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 16 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 16 |